Navigation Links
Analysis of cancer incidence, mortality and survival combined reveals encouraging European trends
Date:7/1/2008

or example, might be real, i.e. because of increasing risks due to previous cancer-causing or promoting agents, or they might be due to improvements in the completeness of the cancer registry, changes in diagnostic criteria, or effects of early detection methods such as population screening. Likewise, improving cancer survival could be due to better treatment, but also because of earlier diagnosis of patients in whom cancer would otherwise be detected much later or who would even never have had clinical disease."

The researchers found that generally in the more prosperous countries of Northern and Western Europe the trend was downwards for cancer incidence; the exceptions were for obesity-related cancers such as colorectal and postmenopausal breast cancer, and for tobacco-related cancers in women, such as lung cancer.

Incidence and mortality from tobacco-related cancer decreased for men in Northern, Western and Southern Europe, they increased for both sexes in Central Europe and for women nearly everywhere in Europe. With the exception of smoking-related cancers, mortality trends generally in most cancers were moving downwards for most of Europe.

Survival rates for most cancers generally improved. The researchers say this is due to better access to specialised diagnostics, staging and treatment. "Marked effects of organised or opportunistic screening became visible for breast, prostate and melanoma in the wealthier countries," they report. For instance, although the incidence of breast cancer continues to rise in most countries, deaths are declining and survival is improving. The rising incidence and survival rates are partly influenced by the presence of organised breast cancer screening programmes and even opportunistic screening that increases the detection of smaller and less aggressive tumours, resulting in decreased mortality after five to eight years. Survival and mortality is influenced also by improved staging and treatment, such
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
ECCO-the European CanCer Organisation
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Caris Diagnostics Providing KRAS Mutational Analysis for Colon Cancer Patients
2. The DataTrace(R) RF System, the Latest High Performance Radio Data Logger for Real-Time, Process Data Collection, Reporting, and Analysis Is Launched
3. Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance
4. Analysis of Millions of U.S. Births Shows Association Between Birth Defects and Preterm Birth
5. Data re-analysis shows drug finasteride reduces risk for most prostate cancers
6. Carnegie Mellon engineering researchers automate analysis of protein patterns
7. Queen Rania Launches Situation Analysis of Children in Jordan Highlighting Jordans Progress in Improving Quality of Life; 6 Ministers Commit to Further Improving Results
8. New analysis shows DAYTRANA offered ADHD symptom control for 12 months
9. PA Governor Says Financial Analysis Shows Nothing Stands in Way of Senate Action to Help Pennsylvanias Uninsured
10. Analysis of alcoholics brains suggests treatment target
11. New Lewin Group Analysis: Medicare Cuts for Nursing Facility Care Could Have Economic Impact Up to $4.2 Billion, Threaten Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3aTyr Pharma to Present at Japan Biopharma Partnering Conference 58295 1aTyr Pharma to Present at Japan Biopharma Partnering Conference 58295 2Free Wheelchair Mission Listed by Ministry Watch as Top 30 Shining Light Exemplary Ministry for 2008 58293 1Free Wheelchair Mission Listed by Ministry Watch as Top 30 Shining Light Exemplary Ministry for 2008 58293 2Virginia Now Owns Three Top National Business Rankings 14267 1Virginia Now Owns Three Top National Business Rankings 14267 2